6 Jul 2017 Jahr - The JAMA Viewpoint article by Dr. Scott Gottlieb
and Dr. Janet Woodcock entitled, “Marshaling FDA
Benefit-Risk Expertise to Address the Current
Opioid Abuse Epidemic," was published.
Following the FDA’s request, Endo announced
that it would voluntarily remove reformulated
Opana ER from the market.
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
